A Letter From Cannabis Bioscience International Holdings CEO Dante Picazo Regarding Actual Progress and Plans for 2024

About this update from Cannabis Bioscience International Holdings, Inc.

[{"type":"text","content":"Houston, Texas--(Newsfile Corp. - December 18, 2023) - Cannabis Bioscience International Holdings, Inc. (OTC Pink: CBIH). CEO Dante Picazo sending a letter to all shareholders. Dear shareholders, A great friend called me last week and said \"Congratulations! Getting the S-1 rendered effective was like giving birth to triplets twice\" and my response was \"Exactly, like triplets that had the cord wrapped around each neck, in a Podalic version, twice\". Not easy. You get the picture. However, the only thing that our firm can not possibly do is to litigate the past, instead, we are putting bygone dates in our rear-view mirror, and moving forward. In consequence, allow me to provide a perspective for our company, particularly now that the year 2023 is close to an end. And, for every shareholder and employee of our company who stuck with us through thick and thin, permit me to thank you for all the support that you have provided to the company. Now is my turn to once more start to reconstruct our vision for the future. As you can imagine, our company did not sit still during the last couple of years waiting for our housekeeping matters to materialize, instead we worked non-stop to enhance our formulations arsenal, which includes medicines for anxiety, PTSD, shingles, malignant neoplasms, among many others; and allow me to briefly describe two of our recently developed formulations that have captivated each synapsis in my brain. Our mini-clinical trials, collection of data, or trial programs, will not be conducted in any territory, city, state, or country where the use of specific cannabinoids is restricted or prohibited. And distribution of products will also comply with any local, state, medical regulatory board, or country regulation. Principally, I am fascinated by Orthocann, our formulation for the treatment of osteoarthritis. My excitement stems from the fact that this could perhaps be the first injection in the world that could help to rebuild the cartilage tissue that is often damaged by so many factors including injuries and age-related illnesses. While we cannot reveal/disclose the cocktail of active compounds that we have composed, I can inform you that it includes the proper cannabinoid molecules and other natural substances that promise to provide relief with less possible side effects than other traditional treatments. H...

More updates from Cannabis Bioscience International Holdings, Inc.